Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TCRX
TSCAN THERAPEUTICS, INC.
NASDAQ
$0.75
▲ UP 0.44% (0.00)

KEY STATISTICS

Market Cap$46.02 M
52w High$2.57
52w Low$0.72
Dividend Yield—
Frequency—
P/E-0.83
Volume150.69K
Shares Out.61.07M

COMPANY

LEADERSHIP

Gavin MacBeath
CHIEF EXECUTIVE
Gavin MacBeath

COMPENSATION 2026

Salary$665,000
Stock Awards$0
Incentive Plan Pay$139,650
All Other Comp.$14,000
Total$2,801,450

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 16, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
138

PRICE TARGET

Target High$12.00
Target Low$3.00
Target Median$7.50
Target Consensus$7.50

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$1.45M
NOV
11
WED

PRICE

$0.75 ▲ UP 0.44% (+$0.00)
$0.75$0.75$0.76$0.769:48 AM10:50 AM11:52 AM12:54 PM1:55 PM2:57 PM3:59 PM0.75

About TScan Therapeutics, Inc.

https://www.tscan.com ↗

TScan Therapeutics, a preclinical-stage biotech in Waltham, MA, develops T cell receptor therapies for cancer and infectious diseases, including vaccines and collaborations with Novartis.

INDUSTRY

Biotechnology

A PRODUCT TSCAN THERAPEUTICS, INC. IS KNOWN FOR

TSC-203-A0201
TSC-203-A0201

TSC-203-A0201 is a TCR-engineered T-cell therapy targeting PRAME, marking TScan's first 'ImmunoBank' product in Phase 1 trials for solid tumors like melanoma and lung cancer, with patient dosing beginning in May 2024.

COMPETITORS

COMPETITOR
FATE COMPARE
IOVA COMPARE
TCRT COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Reportable Segment$2.51M $2.57M ▲$982K ▼$1.05M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.8M
IWC
0.01% · 169.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
56.85%
HOLDERS
96
TOP 12 OF 96 · RANKED BY POSITION SIZE
Lynx1 Capital Management LP
8.0M sh · $8.02M
Bvf Inc/Il
5.6M sh · $5.62M
Blackrock Inc.
4.5M sh · $26.1M
Baker Bros. Advisors LP
2.8M sh · $5.07M
Vanguard Group Inc
2.5M sh · $2.48M
Blackrock, Inc.
2.4M sh · $4.34M
Propel Bio Management, LLC
1.9M sh · $3.52M
Abrdn Plc
1.8M sh · $1.79M
Millennium Management LLC
1.5M sh · $1.47M
Renaissance Technologies LLC
1.4M sh · $1.38M
Deer Ix & Co. Ltd.
1.2M sh · $9.35M
Deer Management Co. LLC
1.2M sh · $1.25M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Klencke Barbara
Purchase · 67.0K shares
2026-05-20
★
DIRECTOR
BAKER BROS. ADVISORS LP
Purchase · 67.0K shares
2026-05-20
★
DIRECTOR
Woods Keith
Purchase · 67.0K shares
2026-05-20
★
DIRECTOR
Nicholson Garry A
Purchase · 67.0K shares
2026-05-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
NEUTRAL 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Needham BUY Wedbush OUTPERFORM BTIG NEUTRAL

SECTORS PEERS

PEERPRICE
RLMD$4.33COMPARE
IMUX$15.40COMPARE
VXRT$0.50COMPARE
FBIO$2.77COMPARE
ACRV$2.06COMPARE
ACET$9.06COMPARE
XBIT$2.27COMPARE
PMVP$1.22COMPARE